Clinical Trial Update: Bucillamine Study of Holding Remission After Infliximab Dose-off [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update examining holding remission after stopping infliximab in rheumatoid arthritis; no status results reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Bucillamine (bucillamine)
• Remicade (infliximab)

Snippet

Sponsor: Saitama Medical University | Conditions: Rheumatoid Arthritis | Phase 4 | Status: UNKNOWN